Urtoxazumab
Urtoxazumab (TMA-15) is a humanizedized monoclonal antibody against Shiga toxin (Stx) 2.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 502496-16-4
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
Isotype
Human IgG2 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
Shiga toxin
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:5-week-old male DBA/2J mice, STEC B2F1-infection model[1]
-
Dosage:0.25, 0.5, 1.0, 2.0 and 2.5 mg/kg
-
Administration:Intravenous administration, 1 h before and 12, 24, and 48 h after infection
-
Result:Pretreatment completely protected the infected mice from death, the efficacy of the low dose (0.25 mg/kg) was partial when administered at 12 and 24 h after infection, but the efficacy of the high dose (2.5 mg/kg) was still complete. Prevented death from B2F1 infection in all 20 animals at 1.0 and 2.0 mg/kg 24 h after infection.
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Anwendung
ELISA, FACS, Functional assay
Chemical Information
-
CAS. Nr. 502496-16-4
-
SMILES
[Urtoxazumab]
-
Synonyms
HuVTm1.1; TMA-15
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)